Monopar Therapeutics (MNPR) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental assessment scores 5.08/10, rated neutral. Strengths include high PB‑ROE, solid cash‑to‑market value, strong inventory turnover and fixed‑asset efficiency. Weaknesses are negative Asset‑MV and Revenue‑MV, and low income‑tax‑to‑profit ratio. Overall, fundamentals are balanced, warranting selective interest.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value2.40

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value-5.45

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight16.52%

1M Return5.94%

Is MNPR fundamentally strong?

MNPR scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -14.22% ROE, 0.00% net margin, -26.90 P/E ratio, 2.68 P/B ratio, and 54.99% earnings growth, these metrics solidify its Netural investment rating.